Literature DB >> 17428951

Production and evaluation of reagents for detection of Histoplasma capsulatum antigenuria by enzyme immunoassay.

Mark D Lindsley1, Heather L Holland, Sandra L Bragg, Steven F Hurst, Kathleen A Wannemuehler, Christine J Morrison.   

Abstract

The detection of urinary Histoplasma capsulatum polysaccharide antigen (HPA) by enzyme immunoassay (EIA) has proven useful for the presumptive diagnosis of histoplasmosis in AIDS patients. Assay limitations include (i) detection of a largely uncharacterized antigen and (ii) difficulty in reproducibly generating antibodies for use in the EIA. To improve antibody production for use in this test and to better understand the antigen being detected, we compared rabbit antibodies elicited using various immunization schedules, routes, and H. capsulatum-derived antigens. Antibodies were evaluated by EIA for their ability to detect purified H. capsulatum C antigen (C-Ag) and antigenuria. Reported as enzyme immunoassay (EI) units (the A(450) with antigen divided by the A(450) without antigen), results demonstrated that intravenous immunization of rabbits with whole, killed yeast-phase cells (yeast-i.v. regimen) produced antibodies giving the highest EI values in the C-Ag EIA (mean EI units +/- standard deviation, 14.9 +/- 0.6 versus 6.4 +/- 0.4 for rabbits immunized with C-Ag versus 2.4 +/- 0.3 for all other regimens combined). Yeast-i.v. antibodies were highly sensitive for the detection of antigenuria in patients with histoplasmosis, as shown by the following results: 12/12 patients compared to 10/12, 6/12, 3/12, and 3/12, respectively, for antibodies from rabbits immunized with (i) C-Ag; (ii) whole, killed yeast-phase cells administered subcutaneously and intramuscularly; (iii) yeast-phase culture filtrates; and (iv) HPA-positive urine. Rabbits immunized using the yeast-i.v. regimen also gave higher peak antibody titers than rabbits immunized by any other regimen (P < 0.03), and their antibodies were most comparable in reactivity to antibodies produced for use in the standard HPA-EIA test (P < 0.001). Therefore, rabbits immunized using the yeast-i.v. regimen produced the most sensitive antibodies with the highest titers for detection of C-Ag and antigenuria in histoplasmosis patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428951      PMCID: PMC1951087          DOI: 10.1128/CVI.00083-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

Review 2.  Current diagnosis of histoplasmosis.

Authors:  L Joseph Wheat
Journal:  Trends Microbiol       Date:  2003-10       Impact factor: 17.079

3.  False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies.

Authors:  L J Wheat; P Connolly; M Durkin; B K Book; A J Tector; J Fridell; M D Pescovitz
Journal:  Transpl Infect Dis       Date:  2004-03       Impact factor: 2.228

4.  A retrospective review of lesions associated with the use of Freund's adjuvant.

Authors:  J R Broderson
Journal:  Lab Anim Sci       Date:  1989-09

5.  Immunochemical analysis of the H and M glycoproteins from Histoplasma capsulatum.

Authors:  R M Zancopé-Oliveira; S L Bragg; E Reiss; J M Peralta
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

6.  Cellular immune activity of a galactomannan-protein complex from mycelia of Histoplasma capsulatum.

Authors:  E Reiss; W O Mitchell; S H Stone; H F Hasenclever
Journal:  Infect Immun       Date:  1974-10       Impact factor: 3.441

7.  Risk factors for death in acquired immunodeficiency syndrome-associated disseminated histoplasmosis.

Authors:  Elizabeth de Francesco Daher; Fernando Antonio de Sousa Barros; Geraldo Bezerra da Silva Júnior; Christianne Fernandes Valente Takeda; Rosa Maria Salani Mota; Marúsia Thomaz Ferreira; Julieta Cunha Martins; Soraya Alves Jacinto Oliveira; Oswaldo Augusto Gutiérrez-Adrianzén
Journal:  Am J Trop Med Hyg       Date:  2006-04       Impact factor: 2.345

8.  A large histoplasmosis outbreak among high school students in Indiana, 2001.

Authors:  Shadi Chamany; Sara A Mirza; John W Fleming; James F Howell; Steven W Lenhart; Vincent D Mortimer; Maureen A Phelan; Mark D Lindsley; Naureen J Iqbal; L Joseph Wheat; Mary E Brandt; David W Warnock; Rana A Hajjeh
Journal:  Pediatr Infect Dis J       Date:  2004-10       Impact factor: 2.129

9.  Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.

Authors:  R A Hajjeh; P G Pappas; H Henderson; D Lancaster; D M Bamberger; K J Skahan; M A Phelan; G Cloud; M Holloway; C A Kauffman; L J Wheat
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

10.  Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.

Authors:  Mitchell Goldman; Robert Zackin; Carl J Fichtenbaum; Daniel J Skiest; Susan L Koletar; Richard Hafner; L Joseph Wheat; Peter M Nyangweso; Constantin T Yiannoutsos; Carol T Schnizlein-Bick; Susan Owens; Judith A Aberg
Journal:  Clin Infect Dis       Date:  2004-04-28       Impact factor: 9.079

View more
  7 in total

1.  Evaluation of reagents for detection of Histoplasma capsulatum antigenuria.

Authors:  L Joseph Wheat
Journal:  Clin Vaccine Immunol       Date:  2007-10

2.  Multicenter Validation of Commercial Antigenuria Reagents To Diagnose Progressive Disseminated Histoplasmosis in People Living with HIV/AIDS in Two Latin American Countries.

Authors:  Diego H Cáceres; Blanca E Samayoa; Eduardo E Arathoon; Beatriz L Gómez; Narda G Medina; Angela M Tobón; Brenda J Guzmán; Danicela Mercado; Angela Restrepo; Tom Chiller
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

Review 3.  Diagnosis of histoplasmosis: current status and perspectives.

Authors:  María Agustina Toscanini; Alejandro David Nusblat; María Luján Cuestas
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-15       Impact factor: 4.813

4.  Nonculture diagnostic methods for invasive fungal infections.

Authors:  L Joseph Wheat
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

5.  Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients.

Authors:  Christina M Scheel; Blanca Samayoa; Alejandro Herrera; Mark D Lindsley; Lynette Benjamin; Yvonne Reed; John Hart; Sandra Lima; Blanca E Rivera; Gabriella Raxcaco; Tom Chiller; Eduardo Arathoon; Beatriz L Gómez
Journal:  Clin Vaccine Immunol       Date:  2009-04-08

6.  Validation of an enzyme-linked immunosorbent assay that detects Histoplasma capsulatum antigenuria in Colombian patients with AIDS for diagnosis and follow-up during therapy.

Authors:  Diego H Caceres; Christina M Scheel; Angela M Tobón; Angela Ahlquist Cleveland; Angela Restrepo; Mary E Brandt; Tom Chiller; Beatriz L Gómez
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

7.  Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis.

Authors:  Simon F Dufresne; Kausik Datta; Xinming Li; Ekaterina Dadachova; Janet F Staab; Thomas F Patterson; Marta Feldmesser; Kieren A Marr
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.